Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies |
| |
Authors: | C M Camaggi E Strocchi A Martoni C Zamagni N Cacciari G Robustelli della Cuna L Pavesi M Tedeschi A Silva F Pannuti |
| |
Institution: | (1) Dipartimento di Chimica Organica, Laboratorio ANT di Farmacocinetica e Metabolismo, Università di Bologna, Viale Risorgimento 4, I-40136 Bologna, Italy;(2) Divisione di Oncologia, Ospedale S. Orsola-Malpighi, Bologna, Italy;(3) Divisione di Oncologia Fondazione Clinica del Lavoro, Pavia, Italy;(4) Boehringer Mannheim Italia, Monza, Italy |
| |
Abstract: | The bioequivalence of two megestrol acetate formulations, 160-mg tablets and 160-mg sachets , was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9–1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature. |
| |
Keywords: | Megestrol acetate Pharmacokinetics Bioequivalence |
本文献已被 SpringerLink 等数据库收录! |
|